^
    1d
    A Study in Adults With Desmoid Tumors (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Elpiscience (Suzhou) Biopharma, Ltd.
    New P2 trial
    1d
    Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF (clinicaltrials.gov)
    P3, N=472, Recruiting, Sunshine Lake Pharma Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    Phase ll Study of HEC585 in Patients With IPF (clinicaltrials.gov)
    P2, N=270, Active, not recruiting, Sunshine Lake Pharma Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Dec 2026 | Trial primary completion date: May 2024 --> Jul 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    2d
    Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis (clinicaltrials.gov)
    P2/3, N=196, Not yet recruiting, Nanfang Hospital, Southern Medical University
    New P2/3 trial
    |
    Reblozyl (luspatercept-aamt)
    2d
    SOTERIA: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) (clinicaltrials.gov)
    P3, N=815, Recruiting, Merck Sharp & Dohme LLC
    Trial initiation date
    |
    Winrevair (sotatercept-csrk)
    3d
    TAK-226-3001: A phase 3 trial comparing elritercept versus epoetin alfa for treatment of anemia due to lower-risk MDS in ESA-nave adults who require RBC transfusions (2025-523544-12-00)
    P2/3, N=16, Not yet recruiting, Takeda Development Center Americas Inc.
    New P2/3 trial
    |
    elritercept (KER-050)
    6d
    Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension (clinicaltrials.gov)
    P4, N=30, Completed, Mayo Clinic | Active, not recruiting --> Completed
    Trial completion
    |
    Winrevair (sotatercept-csrk)
    7d
    ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (clinicaltrials.gov)
    P3, N=360, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Reblozyl (luspatercept-aamt)
    7d
    REPEAT: Real-life-persistence to Antifibrotic Treatments (clinicaltrials.gov)
    P=N/A, N=10646, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed
    Trial completion
    |
    nintedanib
    8d
    Oncologic strategies and options for the management of metastatic thymic carcinoma. (PubMed, Mediastinum)
    Novel therapeutic approaches are emerging, including PRMT5 inhibitors in MTAP-deficient tumors, TROP-2-directed antibody-drug conjugates (e.g., sacituzumab govitecan), and chimeric antigen receptor (CAR) T-cell therapies targeting mesothelin. Bispecific agents such as bintrafusp alfa and ivonescimab, which co-target various pathways, offer innovative strategies. Despite these advances, TC remains a challenging malignancy with no standardized treatment algorithm. Collaborative efforts across institutions will be essential to accelerate progress and improve outcomes in this rare disease.
    Review • Journal • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • MTAP (Methylthioadenosine Phosphorylase) • MSLN (Mesothelin)
    |
    KIT mutation
    |
    Trodelvy (sacituzumab govitecan-hziy) • bintrafusp alfa (M7824) • Yidafan (ivonescimab)
    8d
    CADENCE: A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) (clinicaltrials.gov)
    P2, N=164, Completed, Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Active, not recruiting --> Completed
    Trial completion
    |
    Winrevair (sotatercept-csrk)
    8d
    N'FORCE: Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=131, Not yet recruiting, Groupe Oncologie Radiotherapie Tete et Cou
    New P2 trial
    |
    Opdivo (nivolumab) • ficerafusp alfa (BCA101)